Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center

Clinical Toxicology

Volumn 44, Issue 3, 2006, Pages 243-247

  Stojanovski, Sasko D ^a   Robinson, Renee F ^a   Baker, S David ^b   Casavant, Marcel J ^a   Hayes, John R ^c   Nahata, Milap C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c O   (United States)

Author keywords

Atomoxetine hydrochloride; Overdose exposures; Pediatrics; Strattera

Indexed keywords

ATOMOXETINE; NORADRENALIN UPTAKE INHIBITOR; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADOLESCENT; AGITATION; ARTICLE; ATTENTION DEFICIT DISORDER; DOSE RESPONSE; DRUG EXPOSURE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG SELECTIVITY; ERYTHEMA; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE FACILITY; HEART RATE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; LETHARGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; POISON CENTER; RASH; SCHOOL CHILD; VOMITING; CHILD; DRUG SURVEILLANCE PROGRAM; RETROSPECTIVE STUDY;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; POISON CONTROL CENTERS; PROPYLAMINES; RETROSPECTIVE STUDIES;

EID: 33745062868     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650600584311     Document Type: Article

References (16)

1. Garland M, Kirkpatrick P. Fresh from the pipeline: atomoxetine hydrochloride. Nat Rev Drug Discov 2004; 3:385-386.
2. Wheeler EC. Lilly address ADD drug issues. Recorder 2005; 110:A1.
3. The Top 300 Prescriptions for 2004 by Number of US Prescriptions Dispensed 5, July 2005. 〈http://www.rxlist.com/top200.htm〉.
4. Eli Lilly and Company. Strattera® (atomoxetine) package insert. Indianapolis, IN, 2002.
5. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25:3065-3083.
6. Singer AJ, Gulla J, Thode HC. Parents and practitioners are poor judges of young children's pain severity. Acad Emerg Med 2002; 9:609-612.
7. Stanford EA, Chambers CT, Craig KD. A normative analysis of the development of pain-related vocabulary. Pain 2005; 114:278-284.
8. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone S, Rea J, Witcher J, Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11:251-265.
9. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee F, Spencer T, the Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled dose-response study. Pediatrics 2001; 108:83-91.
10. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee F, Sangal R, Saylor K, West S, Kelsey D, Wernicke J, Trapp N, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159:1896-1901.
11. Spiller HA, Lintner CP, Winter ML. Atomoxetine (Strattera®) exposures in children. J Toxicol Clin Toxicol 2004; 42:720.
12. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J. Cardiovascular effects of atomoxetine in children, adolescent, and adults. Drug Saf 2003; 26:729-739.
13. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63:50-55.
14. Barker MJ, Benitez JG, Ternullo S, et al. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Human Toxicol 2004; 46:130-132.
15. Sawant S, Daviss S. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry 2004; 161:757.
16. Cantrell FL, Nestor M. Benign clinical course following atomoxetine overdose. Clin Toxicol 2005; 1:57.